Amanta Healthcare Q1FY27 Results

Amanta Healthcare reported Q1FY27 revenue of ₹68.80 crore, a 5.4% increase year-on-year.

Reader Takeaway: Revenue grows steadily, but margin compression and rising costs dent profits.

What just happened

For the quarter ended June 30, 2026 (Q1FY27), Amanta Healthcare's revenue grew 5.4% to ₹68.80 crore from ₹65.31 crore in Q1FY26. However, EBITDA saw a 4.2% decline to ₹15.18 crore, with EBITDA margins shrinking by 200 basis points to 22%. Profit After Tax (PAT) fell 5.6% to ₹3.31 crore from ₹3.50 crore in the prior year's quarter.

Why this matters

The revenue growth indicates sustained demand and effective pricing strategies. However, the decline in profitability, particularly the contraction in EBITDA and PAT margins, signals challenges from rising operational expenses and increased finance costs due to new debt. This impacts the company's bottom line and overall financial health.

The backstory

Amanta Healthcare has been investing in expanding its manufacturing capabilities. This includes ongoing projects like the Steriport Plant (expected commissioning Q2FY27), SVP Expansion (targeted completion Q4FY27), and a captive solar power project.

What changes now

The company aims for these expansions to boost capacity, efficiency, and operating leverage. The successful commissioning of these projects could lead to improved financial performance in future quarters.

Risks to watch

Key risks include the impact of rising raw material and employee costs on margins, higher finance costs from debt, and potential delays in project commissioning. Successful execution of expansion plans is critical.

Peer comparison

While direct comparable financial data for peers in the specific quarterly results is not provided in the filing, Amanta's performance should be viewed against industry trends in pharmaceutical manufacturing, where cost pressures are common.

Context metrics (time-bound)

Revenue for Q1FY27 stood at ₹68.80 crore, up 5.4% from Q1FY26's ₹65.31 crore. EBITDA was ₹15.18 crore, down 4.2% from ₹15.85 crore. PAT was ₹3.31 crore, a 5.6% decrease from ₹3.50 crore.

What to track next

Investors will be watching the progress of the Steriport and SVP expansion projects, the operationalization of the captive solar power plant, and the company's ability to manage cost inflation and debt servicing.